Targeted therapy for prostate cancer: The Memorial Sloan-Kettering Cancer Center approach

Seminars in Oncology

Volumn 23, Issue 6 SUPPL. 14, 1996, Pages 41-48

  Slovin, S F ^a   Livingston, P O ^a   Rosen, N ^a   Sepp Lorenzino, L ^a   Kelly, W K ^a   Mendelsohn, J ^a   Scher, H I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ANDROGEN; CANCER VACCINE; DOXORUBICIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; MUCIN; PROSTATE SPECIFIC ANTIGEN; QS 21; RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0030471920     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)